[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-associated-dysfunction-steatohepatitis-mash\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-associated-dysfunction-steatohepatitis-mash":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100629594","expanded-studies-on-the-scapis-stockholm-reexamination-cohort-100629594",false,"NCT07476703","Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination","SCAPIS-ReEx","Inclusion Criteria: Subjects already included in the main \u002F general SCAPIS reexamination study in Stockholm.\n\nExclusion Criteria: Inability to provide consent.",true,"ALL","56 Years","74 Years",{"count":22,"type":23},1400,"ESTIMATED","OBSERVATIONAL","The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet.\n\nSCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.:\n\nEXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health.\n\nEXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.",[27,28,29,30,31,32,33,34,35,36,37,38],"Coronary Artery Disease","Arterial Stiffness, Blood Pressure","AORTIC VALVE DISEASES","Mitral Valve Stenosis and\u002For Insufficiency","Heart Failure","Pulmonary Disease, Chronic Obstructive (COPD)","Steatohepatitis","Inflammation Biomarkers","Lipid Profile","Oral Microbiota","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Associated-dysfunction Steatohepatitis (MASH)",[40,41,42,43,44,45,46,47],"coronary artery disease","arterial stiffness","MASLD","COPD","inflammation","dyslipidemia","aortic aneurysm","oral microbiota","RECRUITING","2026-03-12",{"date":51,"type":52},"2026-03-17","ACTUAL",{"date":54,"type":52},"2024-04-08",{"date":56,"type":23},"2026-08-30",{"name":58,"class":59},"Danderyd Hospital","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":60},"100574805","characterization-and-management-of-metabolic-dysfunction-associated-fatty-liver-disease-mafld-100574805","NCT06764056","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.","METAfoie","Inclusion Criteria:\n\n* Body mass index between 30 and 50 kg\u002Fm2;\n* Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis.\n\nExclusion Criteria:\n\n* Type 1 diabetes diagnosis;\n* Alcohol consumption exceeding recommendations \\[\\>140 g\u002Fweek (women) and \\>210 g\u002Fweek (men)\\];\n* Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.);\n* Pharmacological treatment targeting obesity active or ended in the last 3 months;\n* Bariatric surgery;\n* Gastro-intestinal pathologies (GI cancers, IBD, etc.);\n* Capsulated probiotics consumption;\n* Antibiotic treatment in the last 3 months;\n* Pregnancy;\n* Cirrhosis diagnosis (hepatic decompensation).","18 Years",{"count":71,"type":23},120,"INTERVENTIONAL",[74],"NA","The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is:\n\nDoes an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity?\n\nParticipants will either participate in one of three groups:\n\n* Nutrition: Participant will only have a regular follow-up with a registered dietician;\n* Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician;\n* Semaglutide: Participants will start a new medication targeting obesity.",[77,38,78],"Metabolic Associated Fatty Liver Disease","Obesity",[78,80,81,82,83,84,85,86,87],"Metabolic associated fatty liver disease","GLP-1 receptor analogs","Pharmacotherapy","Nutrition","Transient elastography","Semaglutide","Microbiome","Lipidomics","NOT_YET_RECRUITING","2025-01-07",{"date":91,"type":52},"2025-01-08",{"date":93,"type":23},"2025-01",{"date":95,"type":23},"2026-05",{"name":97,"class":59},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval"]